Kim A Reiss (Reiss Binder)
Associate Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania
Assistant Program Director , Hematology/Oncology Fellowship at University of Pennsylvania
Member, Abramson Cancer Center
Co-Leader, Cancer Therapeutics Program, University of Pennsylvania
Department: Medicine
Contact information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-305
3400 Civic Center Blvd
Philadelphia, PA 19104
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-305
3400 Civic Center Blvd
Philadelphia, PA 19104
Office: 215-360-0735
Fax: 215-662-4646
Fax: 215-662-4646
Education:
BA (Psychology)
Colby College, 2002.
Post BA (Pre-Med)
Johns Hopkins University , 2003.
MD (Medicine)
Penn State College of Medicine , 2008.
BA (Psychology)
Colby College, 2002.
Post BA (Pre-Med)
Johns Hopkins University , 2003.
MD (Medicine)
Penn State College of Medicine , 2008.
Post-Graduate Training
Intern, Internal Medicine, Johns Hopkins University , 2008-2009.
Resident , Internal Medicine, Johns Hopkins University , 2009-2011.
Clinical Research Fellow, Department of Medical Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University , 2012-2015.
Chief Fellow, Medical Oncology Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital , 2014-2015.
Permanent linkIntern, Internal Medicine, Johns Hopkins University , 2008-2009.
Resident , Internal Medicine, Johns Hopkins University , 2009-2011.
Clinical Research Fellow, Department of Medical Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University , 2012-2015.
Chief Fellow, Medical Oncology Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital , 2014-2015.
Description of Itmat Expertise
Clinical trials in gastrointestinal malignancies with a focus in pancreatic cancer and DNA repair pathways.Selected Publications
Ryan Hood, Srishti Rathore, Nicholas Seewald, Kim A. Reiss: Association of BRCA1/2 pathogenic variants with primary tumor location and metastatic organotropism in pancreatic adenocarcinoma. ASCO 2024, Chicago, IL June 2024.Bariq Jafry, Syed Kazmi, Kim A. Reiss, Salwan Al Mutar, Timothy Brown: Post-progression therapies and outcomes for patients with advanced, BRCA-related pancreatic cancer after receipt of PARP inhibitors: A national retrospective cohort study. ASCO 2024, Chicago, IL June 2024.
Sri Anbil, MD and Kim A. Reiss, MD: Targeting BRCA and PALB2 in Pancreatic Cancer. Curr Treat Options Oncol Jan 2024.
Kim A. Reiss, MD; Mark H. O’Hara, MD; Ursina Teitelbaum, MD; Thomas B. Karasic, MD; Charles Schneider, MD; Caroline F. Pratz, CRNP; Katharine Nathanson, MD; Robert H. Vonderheide, MD, DPhil; Susan M. Domchek, MD: A phase II study of maintenance rucaparib in patients with platinum sensitive, advanced pancreatic cancer and a pathogenic germline or somatic variant in BRCA1, BRCA2 or PALB2: A four year survival update. ASCO GI, San Francisco, CA Jan 2024.
Timothy J Brown, MD, Arielle Yablonovitch, PhD, Jacob E Till MD PhD, Jennifer Yen, PhD, Lesli A. Kiedrowski, MS MPH, Ryan Hood BA, Mark H. O’Hara MD, Ursina Teitelbaum MD, Thomas B. Karasic MD, Charles Schneider MD, Erica L. Carpenter, PhD MBA, Katherine Nathanson MD, Susan M. Domchek MD, and Kim A. Reiss MD: The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 After Progression on Rucaparib. Clin Cancer Res Dec 2023.
Ben Boursi, MD, MPH; Paul E. Wileyto, ScD; Ronac Mamtani, MD, MSCE; Susan M. Domchek, MD; Talia Golan, MD; Ryan Hood, BS; Kim A. Reiss, MD: Analysis of BRCA1 and BRCA2-Related Pancreatic Cancer and Survival. JAMA Network Open Nov 2023.
Alison M. Schram, Teresa Macarulla, James Cleary, Cindy Neuzillet, Dirk Arnold, Kim A. Reiss, Tanios Bekaii-Saab, Jordi Rodon, Koichi Goto, Sun Young Rha, Michael Duruisseaux, Natasha Leighl, Benjamin A. Weinberg, Mohammed Najeeb Al Hallak, Andrew K. Joe, Shola Adeyemi, Ernesto Wasserman,Kees-Jan Koeman, Alexander E. Drilon, Eileen M. O’Reilly: Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) pancreatic ductal adenocarcinoma (PDAC). ESMO 2023, Madrid, Spain Oct 2023.
Dylane Wineland, Anh N. Le, Ryan Hausler, Gregory Kelly, Emanuel Barrett, Heena Desai, Brad Wubbenhors3, John Pluta, Paul Bastian, Heather Symecko, Kurt D’Andrea, Abigail Doucette, Peter Gabriel, Kim A. Reiss, Anupma Nayak, Michael Feldman, Susan M. Domchek, Katherine L. Nathanson, Kara N. Maxwell: Biallelic BRCA loss and homologous recombination deficiency in non-breast/ovarian tumors in germline BRCA1/2 carriers. JCO Precision Oncology Aug 2023.
Kim A. Reiss, MD; Sung Chul Hong, MS; Anup K. Kasi, MD; Eileen M. O’Reilly, MD; Shishir K Maithel, MD; Xin Yao, MD; Stanley R Hamilton, MD; Ben Boursi, MD; Michael J. Pishvaian, MD; Samuel J. Klempner, MD; Susan M. Domchek, MD; Paul Catalano, ScD; Elena G. Chiorean, MD; Philp A. Philip, MD; Peter J. O’Dwyer, MD: APOLLO: A Randomized Phase II Double-Blind Study of Olaparib versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation: ECOG-ACRIN EA2192. ASCO 2023, Chicago, IL June 2023.
Vincent Chung, Katherine A Guthrie, Michael J Pishvaian, Kim A. Reiss, Andrew M Lowy, Davendra P Sohal, Sarah Colby, Elad Sharon, Carmen Allegra, Eileen M O'Reilly, E Gabriela Chiorean, Philip A Philip: Randomized Phase II Trial of Olaparib Plus Pembrolizumab vs Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations: SWOG S2001. ASCO 2023, Chicago, IL June 2023.